The Psychedelic Access and Research European Alliance (PAREA) has launched a policy paper in line with a recent meeting on medical psychedelics in the European Parliament.
Global investment firm Psych Capital has announced the completion of its 100% acquisition of life science company Short Wave Pharma.
For the first time since Australia rescheduled MDMA and psilocybin, a shipment of the compounds has been made to the country to be used under the...
Psychedelic therapy company Sunstone Therapies has announced the start of its first study investigating multiple doses of psilocybin in the treatment of major depression disorder (MDD)...
A study from the Centre for Psychedelic Research at Imperial College London has shown that extended DMT IV infusions are safe and well tolerated.
Enveric Biosciences has received a Notice of Allowance (NoA) from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the company’s...
Cybin Inc.
A report has revealed that the consumption of ayahuasca is increasing in several countries.
Activists in Oakland have filed a ballot that seeks to legalise safe and legal access to psychedelics for therapeutic uses.
The University of Exeter, UK, has launched the world’s first post-graduate course on psychedelics.
Drug Science has launched a new consultancy arm with an emphasis on the emerging cannabis and psychedelic medicine markets.
Mind Medicine has confirmed it has completed enrollment of Study MMED007, its Phase 2a study evaluating repeated low-dose administration of MM-120 (LSD) for the treatment of...
